Friday 6 November 2026 Export DXCM’s income statement to Excel — free account

DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024.

Revenue: +11.2%
EPS: 0.00%
Free cash flow: −52.9%
Total debt: +0.31%

Quarter to September 2026, against a year earlier

79.50 4.96 −5.87%

Follow DXCM

Alert me

Market cap: $31.5B
P/E: 32.6×
Fwd P/E: 31.8×
Dividend yield: —
F-score: 8/9
Altman Z: 6.43
Beneish M: −2.70
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

DexCom, Inc. (DXCM) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, DexCom, Inc. (DXCM) trades at a price to free cash flow of 28.8×. Over the past ten years it has ranged from 0.0× (December 2017) to 14,292× (January 2017); the current reading is higher than 24% of that period. That is in line with the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/DXCM/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="DexCom, Inc. price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/DXCM/metrics/price-to-free-cash-flow">DexCom, Inc. (DXCM) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	24.0×	(50.46%)
FY2024	48.5×	(47.71%)
FY2023	92.8×	(36.70%)
FY2022	147×	667.76%
FY2021	19.1×	(84.86%)
FY2020	126×	(14.86%)
FY2019	148×	(21.33%)
FY2018	188×	(2.16%)
FY2017	193×	(98.02%)
FY2016	9,738×	2,238.65%

Period	Price to free cash flow	Change
Sep 2026	29.4×	60.68%
Jun 2026	18.3×	8.29%
Mar 2026	16.9×	(29.63%)
Dec 2025	24.0×	(2.99%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 14,292×

Ten-year median 141×

Current reading's percentile 24

Company	Price to free cash flow
SNN Smith & Nephew SNATS, Inc. compare	7.1×
PHG Koninklijke Philips N.V. compare	14.1×
ZBH Zimmer Biomet Holdings, Inc. compare	18.2×
BSX Boston Scientific Corporation compare	19.3×
GEHC GE HealthCare Technologies Inc. compare	19.9×
STE STERIS plc compare	26.4×
DXCM DexCom, Inc.	28.8×
EW Edwards Lifesciences Corporation compare	41.5×
GKOS Glaukos Corporation compare	360×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

DexCom, Inc. (DXCM) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on DXCM

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on DXCM

Stockrow Weekly